Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Supply Assays for Swiss BVD Program

NEW YORK (GenomeWeb News) – Qiagen said today that it will supply Swiss life sciences firm Microsynth with molecular cador bovine viral diarrhea assays under a multi-year agreement.
Microsynth is one of a few laboratories that has been accredited by the Swiss government to perform tests for BVD, which is one of the most widespread and costly infectious cattle diseases with 60 percent to 80 percent of cattle exposed to the virus, according to Qiagen. The agreement is part of the Swiss national BVD virus eradication program, in which over a million cows are being screened for identification and containment of the disease.
According to the partners, the cador BVDV assay enables testing of pooled samples and is suited for high-throughput settings. Microsynth expects to process as many as 350,000 samples in three months of the program.
In addition to the agreement with Microsynth, Qiagen will supply the Institute of Veterinary Virology at the University of Bern with the assay, QIAamp sample preparation technologies, and BioRobot Universal automation instrument. The institute is an official BVDV reference lab for Switzerland and partnered with Qiagen during development of the PCR-based cador BVDV assay.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.